LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

Kodu・Aktsiate loetelu・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Suletud

SektorTervishoid

7.62 -0.13

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.55

Max

7.62

Põhinäitajad
By Trading Economics
Sissetulek	5.1M 5.1M
Müük	18M 163M
Kasumimarginaal	3.113
Töötajad	580
EBITDA	7.2M 28M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+129.36% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. nov 2025

Turustatistika
By TradingEconomics
Turukapital	-172M 1.7B
Eelmine avamishind	7.75
Eelmine sulgemishind	7.62

Uudiste sentiment

By Acuity

50%

132 / 371 Pingereas Healthcare

BioCryst Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. sept 2025, 18:25 UTC

Suurimad hinnamuutused turgudel

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

27. sept 2025, 07:00 UTC

Tulu

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

27. sept 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26. sept 2025, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26. sept 2025, 20:54 UTC

Tulu

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26. sept 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26. sept 2025, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26. sept 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26. sept 2025, 19:54 UTC

Market Talk

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26. sept 2025, 19:53 UTC

Omandamised, ülevõtmised, äriostud

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26. sept 2025, 19:40 UTC

Tulu

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26. sept 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26. sept 2025, 19:17 UTC

Market Talk

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26. sept 2025, 19:15 UTC

Market Talk

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26. sept 2025, 19:03 UTC

Market Talk

Global Equities Roundup: Market Talk

26. sept 2025, 19:03 UTC

Market Talk

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26. sept 2025, 18:50 UTC

Market Talk

Tulu

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26. sept 2025, 18:36 UTC

Market Talk

Silver Closes Out Week With Strong Surge -- Market Talk

26. sept 2025, 18:02 UTC

Omandamised, ülevõtmised, äriostud

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26. sept 2025, 18:02 UTC

Omandamised, ülevõtmised, äriostud

ING: Global Development Hasn't Received All Necessary Approvals >ING

26. sept 2025, 18:02 UTC

Omandamised, ülevõtmised, äriostud

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26. sept 2025, 17:54 UTC

Market Talk

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26. sept 2025, 16:56 UTC

Market Talk

Tulu

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26. sept 2025, 16:41 UTC

Market Talk

Tulu

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26. sept 2025, 16:26 UTC

Tulu

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26. sept 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

26. sept 2025, 16:12 UTC

Market Talk

Nike Stock Seen With Limited Upside -- Market Talk

26. sept 2025, 15:59 UTC

Market Talk

Global Equities Roundup: Market Talk

26. sept 2025, 15:59 UTC

Market Talk

Nike Seen Showing Progress in Turnaround -- Market Talk

Võrdlus sarnastega

Hinnamuutus

BioCryst Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

129.36% tõus

12 kuu keskmine prognoos

Keskmine 17.5 USD 129.36%

Kõrge 30 USD

Madal 12 USD

Põhineb 6 Wall Streeti analüütiku instrumendi BioCryst Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi BioCryst Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

132 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.